000087700 001__ 87700 000087700 005__ 20200716101449.0 000087700 0247_ $$2doi$$a10.1039/c8dt00298c 000087700 0248_ $$2sideral$$a111275 000087700 037__ $$aART-2019-111275 000087700 041__ $$aeng 000087700 100__ $$aFernández-Moreira, V. 000087700 245__ $$aBioactive and luminescent indole and isatin based gold(i) derivatives 000087700 260__ $$c2019 000087700 5060_ $$aAccess copy available to the general public$$fUnrestricted 000087700 5203_ $$aA series of luminescent monometallic [AuL(PPh 3 )] (1-3) and bimetallic [Au 2 (µ-dppe)L 2 ] (4, 6, 8) and [Au 2 (µ-dppp)L 2 ] (5, 7, 9) complexes, where L is either 4-cyano-indole, isatin, or 5, 7-dimethyl-isatin, and dppe and dppp are 1, 2-bis(diphenylphosphino)ethane and 1, 3-bis(diphenylphosphino)propane, respectively, have been synthesised. X-ray diffraction confirmed the tendency to establish aurophillic interations for those complexes containing dppe. Luminescence studies and theoretical calculations revealed a different origin for both families, i.e. indole and isatin species. Thus, indole derivatives presented a ligand-to-ligand-charge-transfer transition (LLCT) from the indole to the PPh 3 fragment, whereas for the isatin derivatives an intraligand-charge-transfer transition (ILCT) within the isatin fragment is proposed. In both cases, the gold centre was slightly implicated as a ligand-to-metal-charge transfer transition (LMCT) (from the indole/isatin to Au(i)). Cell antiproliferative assays in lung cancer cells (A549), leukemia Jurkat-pLVTHM and Jurkat-shBak cells (cisplatin sensitive and resistant, respectively) showed excellent cytotoxic values (10.11-0.28 µM), showing the leukemia cells to be the most sensitive and the bimetallic species to be the most active agents. Preliminary studies associated the cytotoxicity with a combination of different factors, the metallic fragment being mainly responsible. Remarkably, these complexes are able to inhibit the cellular growth of cisplatin resistant Jurkat-shBak cells highlighting their promising future as an alternative anticancer agent. 000087700 536__ $$9info:eu-repo/grantAgreement/ES/DGA-FSE/E07-17R$$9info:eu-repo/grantAgreement/ES/MINECO-FEDER/CTQ2016-75816-C2-1-P$$9info:eu-repo/grantAgreement/ES/MINECO-FEDER/CTQ2017-88091-P 000087700 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/ 000087700 590__ $$a4.174$$b2019 000087700 591__ $$aCHEMISTRY, INORGANIC & NUCLEAR$$b5 / 45 = 0.111$$c2019$$dQ1$$eT1 000087700 592__ $$a1.048$$b2019 000087700 593__ $$aInorganic Chemistry$$c2019$$dQ1 000087700 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion 000087700 700__ $$aVal-Campillo, C. 000087700 700__ $$aOspino, I. 000087700 700__ $$aHerrera, R.P. 000087700 700__ $$0(orcid)0000-0002-2315-9079$$aMarzo, I.$$uUniversidad de Zaragoza 000087700 700__ $$aLaguna, A. 000087700 700__ $$aGimeno, M.C. 000087700 7102_ $$11002$$2050$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Biología Celular 000087700 773__ $$g48, 9 (2019), 3098-3108$$pDalton Trans.$$tDalton Transactions$$x1477-9226 000087700 8564_ $$s854971$$uhttps://zaguan.unizar.es/record/87700/files/texto_completo.pdf$$yPostprint 000087700 8564_ $$s68261$$uhttps://zaguan.unizar.es/record/87700/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint 000087700 909CO $$ooai:zaguan.unizar.es:87700$$particulos$$pdriver 000087700 951__ $$a2020-07-16-09:05:11 000087700 980__ $$aARTICLE